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47 I N H I B I T I O N O F C E L L P R O L I F E R A T I O N IN C U L T U R E D G R A V E S ' 
R E T R O O C U L A R F I B R O B L A S T S USING A N T I S E N S E O L I G O N U C L E O T I D E S 
TARGETING T H E C-MYC P R O T O O N C O G E N E . Armin E. Heufelder. Rebecca S. 
Bahn*. Onno E. Janssen, and Peter C. Scriba. Molecular Thyroid Research Group, 
Medizinische Klinik, Klinikum Innenstadt der Ludwig-Maximilians-Universität, 
München, Germany, and Div. of Endocrinology*, Mayo Clinic, Rochester, USA. 
Alterations of the connective tissue compartment within the orbit play a central role in 
the evolution of Graves ' ophthalmopathy (GO). The enhanced proliferative and 
metabolic activities of retroocuJar fibroblasts in GO are thought to result, at least in pan. 
from paracrine and autocrine signals delivered both by infiltrating T cells and residential 
cells. Although inhibition of effector cell functions may have therapeutic implications, 
the signal transduction pathways involved have not been determined. Thus, using a 
panel of oligomers complimentary to the translation initiation region of the human 
proto-oncogene c-myc, we have studied the effects of an an antisense approach on these 
cellular functions. Antisense 16-mer phosphorothioate oligodeoxynucleotides (S-ODN) 
concentrations of 1-12 nM markedly reduced the proliferative capacity of cultured 
Graves' retroocular fibroblasts compared to cells treated with sense or randomerized 
oligomers of equal length and GC content (each p<0.001) . Inhibition of cell 
proliferation, as determined by a non-radioactive cell proliferation assay, was 78% -
9 6 % at 24 h with significant inhibition of 58% - 87% maintained through 96 h of cell 
culture. No cell cytotoxicity or changes in cell viability were observed at these 
concentrations. In addition, stimulation of cell proliferation by I L - l a (10 U/ml) and 
P D G F (1 ng/ml) in retroocular fibroblasts was also markedly inhibited by these anti-c-
myc S-ODN (91% and 94 % at 24 h, 66% and 74% at 96 h", respectively). Further, c-
myc antisense oligomers were capable of diminishing glycosaminoglycan (GAG) 
synthesis by Graves ' retroocular fibroblasts both at baseline (rxO.01) and following 
stimulation with I L - l a (10 U/ml; p<0.001) and TGFß (10 ng/ml; p<0.001). In 
conclusion, activation of the c-myc gene may play an important role in Graves' 
retroocular fibroblast proliferation and GAG synthesis. The inhibitory effects of c-myc 
antisense S-ODN on the proliferative and metabolic activity of these cells provides a 
strong rationale to further study the effects of antisense strategies targeting the c-myc 
proto-oncogene. Loss of function analysis using antisense oligonucleotides for the 
suppression of oncogenes or overexpressed growth factors may be a valuable tool for 
studying gene functions of potential relevance to the pathogenesis of GO. 
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